We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Catalent (CTLT) Inks Deal With MigVax for Oral COVID-19 Vaccine
Read MoreHide Full Article
Catalent, Inc. (CTLT - Free Report) recently entered into a development agreement with MigVax to leverage its proprietary Zydis Bio orally disintegrating tablet (“ODT”) technology for delivering the MigVax-101 vaccine. Per the terms of the agreement, Catalent will undertake a feasibility study at its Zydis facility in Swindon, U.K. to formulate MigVax-101 into a Zydis Bio ODT dose form and evaluate its preclinical performance and stability properties.
It is noteworthy to mention that MigVax is an Israeli biopharmaceutical company developing an oral subunit vaccine against COVID-19.
The latest development agreement is expected to further strengthen Catalent’s foothold in the global Oral and Specialty Delivery space.
Rationale Behind the Deal
MigVax’s lead oral vaccine program, MigVax-101, has indicated positive results in preclinical tests. Being an oral formulation, MigVax-101 can offer substantial potential advantages in low-and middle-income countries over currently available first-generation injected vaccines. Some of the advantages include ease of administration, transport and storage, the potential to tackle future variants, and applicability to a broader population. Apart from this, MigVax’s oral approach may allow for mucosal protection, a benefit that may play an important role in preventing infection.
Catalent’s Zydis technology, which creates a freeze-dried tablet that disperses almost instantly in the mouth without water, provides various advantages over traditional oral dosage forms, including improved patient compliance and convenience, among others.
Per Catalent’s management, Zydis Bio technology, which has previously been used to successfully deliver antigens to the oral mucosae, is expected to offer several potential benefits to this program.
MigVax’s management believes that following the transportation of its vaccines using the Zydis Bio technology in unrefrigerated vehicles and storage in standard warehouses, it will be simpler and cost-effective for countries to roll out mass-vaccination programs.
Industry Prospects
Per a report by Future Market Insights, the global oral solid dosage pharmaceutical formulation market is projected to grow from $493.2 billion in 2017 to $926.3 billion by 2027-end at a CAGR of 6.5%. Factors like oral solid dosage forms being cost-effective and easy to manufacture, trouble-free packaging and transportation, and increased chemical and physical stability of said dosage forms are likely to drive the market.
Given the market potential, the latest agreement is expected to provide a significant boost to Catalent’s business globally.
Notable Developments in Oral and Specialty Delivery
In April, Catalent completed a significant expansion of its nasal capabilities at its Morrisville, Research Triangle Park, NC facility to provide improved services for the development and manufacturing of unit and bi-dose nasal spray products.
The same month, Catalent completed the installation and commissioning of four new high-throughput high-bay CGMP (current good manufacturing practices) manufacturing suites at its facility in Kansas City, MO, to increase its capacity and capabilities for producing oral solid dose forms.
Price Performance
Shares of the company have gained 0.7% in the past year against the industry’s 32.5% fall and the S&P 500's 9.4% decline.
Image Source: Zacks Investment Research
Zacks Rank & Key Picks
Currently, Catalent carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the broader medical space are AMN Healthcare Services, Inc. (AMN - Free Report) , HealthEquity, Inc. (HQY - Free Report) and Masimo Corporation (MASI - Free Report) .
AMN Healthcare, carrying a Zacks Rank #2 (Buy) at present, has an estimated long-term growth rate of 1.1%. AMN’s earnings surpassed the Zacks Consensus Estimate in all the trailing four quarters, the average beat being 15.6%.
AMN Healthcare has gained 5.2% against the industry’s 65.3% fall in the past year.
HealthEquity, carrying a Zacks Rank #2 at present, has an estimated long-term growth rate of 20.3%. HQY’s earnings surpassed estimates in two of the trailing four quarters and missed the same in the other two, the average beat being 1.4%.
HealthEquity has lost 19.6% compared with the industry’s 65.3% fall over the past year.
Masimo, carrying a Zacks Rank #2 at present, has an earnings yield of 3.3% against the industry’s negative yield. MASI’s earnings surpassed estimates in the trailing four quarters, the average beat being 4.4%.
Masimo has lost 37.2% compared with the industry’s 21.5% fall over the past year.
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
Catalent (CTLT) Inks Deal With MigVax for Oral COVID-19 Vaccine
Catalent, Inc. (CTLT - Free Report) recently entered into a development agreement with MigVax to leverage its proprietary Zydis Bio orally disintegrating tablet (“ODT”) technology for delivering the MigVax-101 vaccine. Per the terms of the agreement, Catalent will undertake a feasibility study at its Zydis facility in Swindon, U.K. to formulate MigVax-101 into a Zydis Bio ODT dose form and evaluate its preclinical performance and stability properties.
It is noteworthy to mention that MigVax is an Israeli biopharmaceutical company developing an oral subunit vaccine against COVID-19.
The latest development agreement is expected to further strengthen Catalent’s foothold in the global Oral and Specialty Delivery space.
Rationale Behind the Deal
MigVax’s lead oral vaccine program, MigVax-101, has indicated positive results in preclinical tests. Being an oral formulation, MigVax-101 can offer substantial potential advantages in low-and middle-income countries over currently available first-generation injected vaccines. Some of the advantages include ease of administration, transport and storage, the potential to tackle future variants, and applicability to a broader population. Apart from this, MigVax’s oral approach may allow for mucosal protection, a benefit that may play an important role in preventing infection.
Catalent’s Zydis technology, which creates a freeze-dried tablet that disperses almost instantly in the mouth without water, provides various advantages over traditional oral dosage forms, including improved patient compliance and convenience, among others.
Per Catalent’s management, Zydis Bio technology, which has previously been used to successfully deliver antigens to the oral mucosae, is expected to offer several potential benefits to this program.
MigVax’s management believes that following the transportation of its vaccines using the Zydis Bio technology in unrefrigerated vehicles and storage in standard warehouses, it will be simpler and cost-effective for countries to roll out mass-vaccination programs.
Industry Prospects
Per a report by Future Market Insights, the global oral solid dosage pharmaceutical formulation market is projected to grow from $493.2 billion in 2017 to $926.3 billion by 2027-end at a CAGR of 6.5%. Factors like oral solid dosage forms being cost-effective and easy to manufacture, trouble-free packaging and transportation, and increased chemical and physical stability of said dosage forms are likely to drive the market.
Given the market potential, the latest agreement is expected to provide a significant boost to Catalent’s business globally.
Notable Developments in Oral and Specialty Delivery
In April, Catalent completed a significant expansion of its nasal capabilities at its Morrisville, Research Triangle Park, NC facility to provide improved services for the development and manufacturing of unit and bi-dose nasal spray products.
The same month, Catalent completed the installation and commissioning of four new high-throughput high-bay CGMP (current good manufacturing practices) manufacturing suites at its facility in Kansas City, MO, to increase its capacity and capabilities for producing oral solid dose forms.
Price Performance
Shares of the company have gained 0.7% in the past year against the industry’s 32.5% fall and the S&P 500's 9.4% decline.
Image Source: Zacks Investment Research
Zacks Rank & Key Picks
Currently, Catalent carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the broader medical space are AMN Healthcare Services, Inc. (AMN - Free Report) , HealthEquity, Inc. (HQY - Free Report) and Masimo Corporation (MASI - Free Report) .
AMN Healthcare, carrying a Zacks Rank #2 (Buy) at present, has an estimated long-term growth rate of 1.1%. AMN’s earnings surpassed the Zacks Consensus Estimate in all the trailing four quarters, the average beat being 15.6%.
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
AMN Healthcare has gained 5.2% against the industry’s 65.3% fall in the past year.
HealthEquity, carrying a Zacks Rank #2 at present, has an estimated long-term growth rate of 20.3%. HQY’s earnings surpassed estimates in two of the trailing four quarters and missed the same in the other two, the average beat being 1.4%.
HealthEquity has lost 19.6% compared with the industry’s 65.3% fall over the past year.
Masimo, carrying a Zacks Rank #2 at present, has an earnings yield of 3.3% against the industry’s negative yield. MASI’s earnings surpassed estimates in the trailing four quarters, the average beat being 4.4%.
Masimo has lost 37.2% compared with the industry’s 21.5% fall over the past year.